Morphogenesis Gets Closer to a Cancer Vaccine
UF Startup and Sid Martin graduate company Morphogenesis, says it is getting closer to a shot that would treat some skin cancers.
UF Health Unveils Imaging Machine, One of 42 in World, To Tackle Difficult Cancers
UF Health is now the first site in the southeastern United States to house a groundbreaking device that will provide personalized cancer treatment by combining extremely detailed magnetic resonance imaging, or MRI, with precision radiotherapy.
Tampa’s Morphogenesis Wants To Cure Cancer With an Affordable Shot
A group of scientists in Tampa is working to make treating cancer as easy as getting a shot. While most of today's cancer treatments tend to be toxic and expensive, UF startup and UF Innovate | Sid Martin Biotech alum Morphogenesis, Inc., a clinical-stage biotechnology company, is working to develop immunotherapies that are safe and affordable.
Ultimate Goal of This Internship? Help Startup Save Lives
I learned about the importance of helping these medical professionals bring innovative cancer treatments to the market by building financial presentations that lead to the venture funding needed, in hopes to ultimately save lives.
DiaCarta Q&A: Liquid Biopsy for Early Cancer Detection
DiaCarta is initiating a large-scale clinical development program, which will monitor cfDNA levels to determine early treatment outcomes of systemic therapy in all types of stage IV cancer.
UF Researchers Say Marine Products Show Promising Future In Medical Advancements
Many drug research efforts occurring at UF are focused on marine and natural products that will lead to advancements in medications and treatments for cancers. Dr. Hendrik Luesch was involved in a recent discovery of a marine compound off the east coast of Florida named gatorbulin-1 that could potentially be used in the fight against cancer; this discovery highlights the importance of searching the ocean’s biodiversity.
Dialectic Therapeutics Receives FDA Clearance of IND Application for for Its Lead Product Candidate To Treat Cancer
UF startup Dialectic Therapeutics, Inc., a Texas-based biotechnology company focused on creating innovative new technologies to treat cancer, announced that the U.S. Food and Drug Administration (FDA) has concluded that Dialectic may proceed with its clinical investigation for its lead product candidate, DT2216, a unique compound built using its proprietary and novel Antiapoptotic Protein Targeted Degradation (APTaD) technology.
